Abstract:Many clinical studies have shown that induction chemotherapy followed by concurrent chemoradiotherapy improved the survival of locally advanced nasopharyngeal carcinoma (NPC). However, it is still unknown that which induction chemotherapy regimen is the optimal choice. This study focused on the comparison of efficacy and toxicities between induction chemotherapy regimen TPF and GP in locally advanced NPC. Between January 2008 and July 2015, patients with locally advanced NPC (clinical stage III-IVb) were retrospectively analyzed. Inclusion criteria were as follows: (1) pathologically confirmed NPC; (2) clinical stage III-IVb according to the 7th edition of the American Joint Committee on Cancer (AJCC) stage criteria; (3) receiving either TPF regimen plus CCRT or GP regimen plus CCRT; (4) radiotherapy was performed using intensity modulated radiation therapy (IMRT). Exclusion criteria were as follows: (1) patients receiving adjuvant chemotherapy; (2) patients with other malignant diseases. The primary endpoint was overall survival (OS). The Secondary endpoints included progression-free survival (PFS), distant metastasis-free survival (DMFS) and locoregional recurrence-free survival (LRFS). The Kaplan-Meier survival curves and log-rank test were used to evaluate the OS, PFS, LRFS, and DMFS of the two groups. Univariate and multivariate analyses were applied to identify the independent prognostic factors. Chi-square test was performed to compare the toxic effects between the two groups. A total of 80 patients treated with TPF regimen plus CCRT and 80 with GP regimen plus CCRT were eligible for this study. After a median follow-up of 47 months (range 8–97months), no differences were observed between the two groups in terms of 3-year OS (86.1% vs. 94.8%, p = 0.123), PFS (81.1% vs. 90.8%, p = 0.224), DMFS (82.3% vs. 94.1%, p = 0.087), or LRFS (93.6% vs.96.1%, p = 0.794). The results of the multivariate Cox proportional hazard analysis showed that the treatment group was not an independent prognostic factor for OS (HR 2.341; 95% CI 0.878–6.241; p = 0.089), PFS (HR 1.814; 95% CI 0.815–4.036; p=0.145), DMFS (HR 2.343; 95%CI 0.942–5.830; p = 0.067), or LRFS (HR 1.243; 95% CI 0.377–4.103; p = 0.721). Clinical stage was an independent prognostic factor affecting OS (HR 0.198; 95 %CI 0.040–0.975; p = 0.046) and PFS (HR 0.224; 95 %CI 0.062–0.810; p = 0.023).There was significant difference in III-IV hepatic toxicity between the two groups (0 vs. 18.6%, p=0.000). No significant differences were observed in bone marrow suppression and kidney dysfunction between the two arms. GP induction chemotherapy plus CCRT achieved similar survival outcomes to those with TPF induction chemotherapy for locally advanced NPC. However, GP regimen increased grade 3–4 hepatic dysfunction compared with TPF induction chemotherapy. More prospective clinical trials are needed to determine the most effective induction chemotherapy regimen for locally advanced NPC.

Nomogram-aided individual induction chemotherapy regimen selection in advanced nasopharyngeal carcinoma

Optimizing the Induction Chemotherapy Regimen for Patients with Locoregionally Advanced Nasopharyngeal Carcinoma: A Big-Data Intelligence Platform-Based Analysis

Nomogram Predicting the Benefits of Adding Concurrent Chemotherapy to Intensity-Modulated Radiotherapy after Induction Chemotherapy in Stages II–IVb Nasopharyngeal Carcinoma

Cisplatin and Fluorouracil Induction Chemotherapy With or Without Docetaxel in Locoregionally Advanced Nasopharyngeal Carcinoma.

Risk stratification and beneficiary selection among elderly nasopharyngeal carcinoma patients from concurrent chemoradiotherapy combined with induction chemotherapy

WITHDRAWN: Interim Analysis of a Prospective Randomized Non-Inferiority Trial of Cisplatin and Fluorouracil Induction Chemotherapy with or Without Docetaxel in Nasopharyngeal Carcinoma

Optimal induction chemotherapeutic regimen followed by concurrent chemotherapy plus intensity-modulated radiotherapy as first-line therapy for locoregionally advanced nasopharyngeal carcinoma

Efficacy and Toxicity of Three Induction Chemotherapy Regimens in Locoregionally Advanced Nasopharyngeal Carcinoma: Outcomes of 10-Year Follow-Up

Comparing three induction chemotherapy regimens for patients with locoregionally advanced nasopharyngeal carcinoma based on TNM stage and plasma Epstein-Barr virus DNA level

Assessment of Induction Chemotherapy Regimen TPF Versus GP Followed by Concurrent Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma: A Retrospective Cohort Study

Comparison of GP and TPF induction chemotherapy for locally advanced nasopharyngeal carcinoma

Establishing and Applying Nomograms Based on the 8th Edition of the UICC/AJCC Staging System to Select Patients with Nasopharyngeal Carcinoma Who Benefit from Induction Chemotherapy Plus Concurrent Chemoradiotherapy

Assessment of Response to Different Induction Chemotherapy Regimens in Locally Advanced Nasopharyngeal Carcinoma

Efficacy of induction chemotherapy in lymph node-positive stage III nasopharyngeal carcinoma and identification of beneficiaries based on clinical features: A propensity score matching analysis

Induction chemotherapy for the treatment of non-endemic locally advanced nasopharyngeal carcinoma

A Nomogram for the Determination of the Necessity of Concurrent Chemotherapy in Patients With Stage II–IVa Nasopharyngeal Carcinoma

Induction Chemotherapy Followed by Radiotherapy Versus Concurrent Chemoradiotherapy in the Treatment of Different Risk Locoregionally Advanced Nasopharyngeal Carcinoma

Assessment of Concurrent Chemoradiotherapy plus Induction Chemotherapy in Advanced Nasopharyngeal Carcinoma: Cisplatin, Fluorouracil, and Docetaxel versus Gemcitabine and Cisplatin

Nomogram to Predict the Benefit of Additional Induction Chemotherapy to Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma: Analysis of a Multicenter, Phase III Randomized Trial

Therapeutic Evaluation of Induction Chemotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma With Low-risk <i>N</i> Stage A Multicenter Retrospective Study From Nonendemic Region of China

The efficacy of induction chemotherapy or adjuvant chemotherapy added to concurrent chemoradiotherapy in T3-4N0-1M0 nasopharyngeal carcinoma: a propensity score-matched analysis